Breaking News

Replimune skin cancer drug that became FDA flashpoint is rejected again 

April 10, 2026
Pharmalot Columnist, Senior Writer
Skin cancer cells
Markus Schober and Elaine Fuchs, The Rockefeller University/NIH

STAT+ | Replimune skin cancer drug that became FDA flashpoint is rejected again

A cancer drug candidate that, rightly or wrongly, became a flashpoint at FDA, fails on a second try at approval.

By Jason Mast


A new trick for old science, and biotech VCs’ scrambled playbook

In this week's episode, hosts Elaine Chen and Allison DeAngelis dig into what’s unsettling biotech VCs.

By Allison DeAngelis and Elaine Chen


New rules for CDC vaccine panel aim to address lawsuit, empower Kennedy’s allies

The move risks highlighting vaccine policy at a time when the Trump White House is seeking to focus the public elsewhere.

By Helen Branswell and Anil Oza



Alex Hogan/STAT

STAT+ | Up and down the ladder: The latest comings and goings

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

By Ed Silverman


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying Pharmalot? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2026, All Rights Reserved.

No comments